Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

143.72
-1.0900-0.75%
Post-market: 143.58-0.1428-0.10%19:30 EDT
Volume:4.20M
Turnover:605.07M
Market Cap:178.31B
PE:-54.96
High:145.99
Open:145.24
Low:143.50
Close:144.81
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.77
T/O Rate:0.34%
Dividend:3.22
Dividend Rate:2.24%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.07
PE(LYR):21.20

Loading ...

Moderna Inc. Stock Sheds 4.3%, Underperforms Peers

Dow Jones
·
Aug 07

Gilead Sciences (GILD) Stock Price Reflects R And D Shock Not Sales Weakness

Simply Wall St.
·
Aug 06

Vir Biotechnology Q2 Revenue Up, Beats Estimates on Astellas Payment

Reuters
·
Aug 06

Gilead Sciences Declares Q3 2026 Distribution of R$ 1.42 Per Unit for Brgildbdr 000

Reuters
·
Aug 06

Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says

MT Newswires Live
·
Aug 06

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Staar Surgical (STAA) and Elanco Animal Health (ELAN)

TIPRANKS
·
Aug 06

Gilead Sciences Inc Stock (GILD) Moved Down by 3.96% on Aug 5: A Full Analysis

TradingKey
·
Aug 06

Gilead Sciences (GILD) Faces Fresh HIV Access Criticism From AIDS Healthcare Foundation

Simply Wall St.
·
Aug 05

Movement Alert|Gilead Sciences Falls 3.03% in Regular Trading, Q2 Acquisition-Driven R&D Charges Swing Results to Loss Despite Revenue Beat

Market Focus
·
Aug 05

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM)

TIPRANKS
·
Aug 05

RBC Capital Adjusts Gilead Sciences Price Target to $123 From $120, Maintains Sector Perform Rating

MT Newswires Live
·
Aug 05

Immuneering Expects Cash Runway to Fund Operations into 2029

Reuters
·
Aug 05

Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates

Reuters
·
Aug 05

Gilead : Leerink Partners Raises Target Price to $130 from $126

THOMSON REUTERS
·
Aug 05

Gilead Sciences (GILD) Gets a Buy from Wells Fargo

TIPRANKS
·
Aug 05

Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained

TIPRANKS
·
Aug 05

Street View: Gilead's HIV Strength Outshines Long-Term Competitive Worries

Reuters
·
Aug 05

U.S. Research Roundup-Ametek, Ball Corp, McDonald's

Reuters
·
Aug 05

Switzerland's Sandoz H1 Net Sales Rise on Biosimilar Growth

Reuters
·
Aug 05

Gilead : Truist Securities Cuts Target Price to $150 from $156

THOMSON REUTERS
·
Aug 05